Equities Analysts Issue Forecasts for DNTH Q1 Earnings

Key Points

• William Blair predicts that Dianthus Therapeutics will report a Q1 2026 earnings loss of ($0.75) per share, maintaining an "Outperform" rating on the stock.
• The company recently reported its earnings results, showing a loss of ($0.88) per share, which was worse than the consensus estimate of ($0.86) per share.
• Dianthus Therapeutics is currently valued at approximately $603.32 million, with a recent stock price of $18.76 and an average price target of $53.00.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for shares of Dianthus Therapeutics in a note issued to investors on Thursday, August 7th. William Blair analyst M. Minter expects that the company will post earnings of ($0.75) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. William Blair also issued estimates for Dianthus Therapeutics' Q2 2026 earnings at ($0.78) EPS and Q3 2026 earnings at ($0.80) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. The business had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million.

A number of other analysts have also recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Robert W. Baird lowered their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Price Performance

DNTH traded down $0.04 on Monday, reaching $20.21. 59,636 shares of the stock were exchanged, compared to its average volume of 316,865. The company's 50-day moving average price is $19.46 and its 200 day moving average price is $20.00. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $32.27. The firm has a market capitalization of $650.56 million, a PE ratio of -6.22 and a beta of 1.43.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNTH. KLP Kapitalforvaltning AS acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $33,000. JPMorgan Chase & Co. lifted its holdings in shares of Dianthus Therapeutics by 14.0% in the 4th quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock valued at $264,000 after buying an additional 1,490 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Dianthus Therapeutics by 12.2% in the 4th quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after buying an additional 6,552 shares during the period. FMR LLC lifted its holdings in shares of Dianthus Therapeutics by 0.8% in the 4th quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after buying an additional 36,133 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after buying an additional 790 shares during the period. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.